Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
TEMPLE CITY, Calif., Feb. 08, 2017 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, February 27, 2017 . The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host an investment community conference call the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investor section of the company’s website, www.fulgentgenetics.com, and through a live conference call by calling 1-855-321-9535, passcode # 65226206. An audio replay will be available in the investors section of the company’s website or by calling 1-855-859-2056 through March 6, 2017.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 275 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contacts: The Blueshirt Group Bob Jones, 212-871-5570, [email protected] Chris Danne, 415-217-5865, [email protected]
